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Abstract
Purpose When treating metastatic bone disease, relief of
bone pain is often a key outcome. Because pain cannot be
quantified with objective clinical measures, patient-reported
outcome (PRO) measures are required to assess patients'
subjective experience. The goal of the current review was
to examine measures used to assess pain, as well as the
impact of pain on functional status and health-related quality
of life (HRQL), in trials of bisphosphonates for the treat-
ment of bone metastases.
Methods A literature search focused on articles published
from January 1999 to April 2009.
Results A total of 49 articles were located that used
PROs to assess pain-related outcomes of bisphosphonate
treatment for bone metastases. The Brief Pain Inventory
was the most commonly used multi-item instrument.
However, the most common approach for assessing pain
was to administer a single-item scale such as a visual
analog scale, numerical rating scale, or verbal rating
scale. Of the 49 studies, 19 included a PRO assessing
functional status or HRQL.
Conclusions Although pain is an important outcome of
trials examining treatment for bone metastases, the current
review suggests that there is little consistency in PRO mea-
surement across studies. Furthermore, presentation of meas-
ures often lacked clear description, information on
measurement properties, citations, clarity regarding method
of administration, and consistent instrument names. Recom-
mendations are provided for instrument validation within
the target population, assessment of content validity, use of
PRO instruments recently developed for patients with bone
metastases, clear description of instruments, and implemen-
tation of measures consistent with recommendations from
instrument developers.
Keywords Bisphosphonate.Bonemetastases.Bonepain.
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Introduction
Metastatic bone disease is common among patients with
advanced-stage cancer, with prevalence estimates of roughly
70% of patients with advanced breast or prostate cancer and
up to 95% of patients with multiple myeloma [1–4]. When
cancer metastasizes to the bone, it can have profoundly neg-
ative effects on patients. For example, bone metastases often
lead to debilitating and potentially life-threatening skeletal
related events (SREs) such as pathological fractures and ma-
lignant spinal cord compression [2, 3, 5]. Bone metastases are
alsoassociatedwithextremepainanddecreasedhealth-related
quality of life (HRQL) [2, 4, 6, 7].
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bone metastases, including external beam radiotherapy and
analgesics such as nonsteroidal anti-inflammatory medica-
tions and opioid analgesics [1, 4, 5]. One of the primary
treatment approaches is the administration of bisphospho-
nate medication, which has been shown to reduce incidents
of SREs such as pathological fractures, while providing pain
relief and resulting in improved HRQL [3, 5, 8–12]. In
clinical trials examining effectiveness of bisphosphonates,
relief of bone pain is often a key outcome [9, 13, 14].
Because pain cannot be quantified with objective clinical
measures, assessment of pain requires the use patient-
reported outcome (PRO) measures to capture patients' sub-
jective experience of the presence, severity, and impact that
pain exerts on physical, functional, social, and emotional
well-being. Consequently, it is necessary to use well-
developed and validated PRO measures of pain to assess
the effectiveness of existing bisphosphonates and new treat-
ments for patients with bone metastases.
The primary goal of the current review was to examine
PRO measures used to assess pain in trials of bisphospho-
nates for the treatment of bone metastases. These measures
were then evaluated with regard to the FDA guidance on
PROs, first issued in February 2006and updated in December
2009 [15, 16] and the European Medicines Agency reflection
paper [17]. Recommendations are provided for assessment of
pain infuturetrialsoftreatmentsforbonemetastases.AsPRO
measures assessing additional endpoints of HRQL and func-
tional status are often included in bisphosphonate trials [13], a
secondary goal of the current review was to identify and
examine measures of these constructs within trials primarily
assessing pain relief among patients with metastatic disease.
Methods
Literature search
A literature search was performed to identify studies that
used PROs to assess pain and associated functional status or
HRQL in clinical trials of bisphosphonates for patients with
bone metastases. The search was conducted using the
PubMed database (comprised of MEDLINE, HealthStar,
CancerLit, AIDSline, and OLDMEDLINE) and restricted
to articles written in English and published during the 10-
year period from January 1999 to April 2009.
Aninitialsearchidentifiedcitationsmentioningbisphosph-
onates in general or one of four specific bisphosphonate
medications (clodronate, ibandronate, pamidronate, and zole-
dronic acid), yielding 6,449 citations. Then, the bisphospho-
nate search was crossed with the search for articles examining
pain associatedwithbonemetastases(search phrase: metasta*
AND [bone OR skeletal] AND pain), yielding 370 citations.
In addition to identifying patient-reported measures of pain,
this review also aimed to locate studies using PROs to assess
functioning and HRQL related to the pain of bone metastases.
However, a separate search was not conducted to identify
PROs assessing functional status or HRQL because these
articles would be identified within literature search focusing
on pain.
Abstract review
The 370 abstracts were reviewed in order to select articles
for more detailed full-text review. At this stage of the review
process, the goal was to identify and obtain any articles that
could have included a PRO measure. For this project, a
measure was considered to be a PRO if it fit the definition
stated in the FDA Guidance on Patient Reported Outcomes
[15]. In this document, a PRO is defined as “any report of
the status of a patient's health condition that comes directly
from the patient, without interpretation of the patient's re-
sponse by a clinician or anyone else.” PRO instruments may
be patient-completed questionnaires or structured inter-
views. These instruments can be used to assess a wide
variety of concepts, ranging from symptoms to more com-
plex constructs such as functional status or quality of life.
Abstracts were selected for subsequent full-text article
review if they mentioned the following: specific PRO meas-
ures (e.g., FACT-G and BPI), “patient-reported” or “subjec-
tive,” visual analog scale or VAS, constructs that are likely
to be assessed by PROs (e.g., quality of life, function, pain,
pain intensity, pain score, symptomatic improvement, and
symptomatic response), or pain assessed via analgesic use
(e.g., “pain assessed as number of days on opioids”). Clin-
ical, bio-marker, and performance-based measures (e.g.,
Eastern Cooperative Oncology Group Performance Status
[18], Karnofsky Performance Status [19]) were not consid-
ered relevant for the current review of PRO measures be-
cause they do not involve patient reports. Furthermore, the
current review excluded patient-reported measures of con-
structs that were not directly related to pain, functional
status, or HRQL, such as treatment satisfaction and time
spent travelling to the hospital to receive bisphosphonate
infusions. The following types of articles were also exclud-
ed from this review: case studies, review articles, meta-
analyses, studies with a sample size of less than ten patients,
letters, commentaries, retrospective studies (e.g., chart re-
view rather than PRO), and cost-effectiveness studies.
Full-text article review
Based on the abstract review, 68 articles were obtained for
full-text review following the same inclusion/exclusion cri-
teria described above. During this full-text review, several
additional study characteristics were considered when
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view aimed to identify PROs used to assess outcomes of
bisphosphonate trials. Therefore, articles in which PROs
were administered only at baseline were excluded. Also
excluded were studies focused only on instrument validation
without reporting trial outcomes Similarly, PRO measures
mentioned in the “Methods” section without subsequent
results were excluded from this review. Articles were also
excluded if they reported assessment of pain or another
construct that was likely based on a PRO, but did not
provide a name or description of a PRO measure.
When an original article and a secondary analysis of the
same trial were both published within the 10-year time
window of the current review, the secondary analysis was
excluded in order to avoid double-counting individual stud-
ies. However, two secondary analyses were included in the
current review because the primary analysis was not pub-
lished within the 10-year time window of this review [20,
21]. Furthermore, two additional secondary analyses were
included in this review because they focus on PRO results
that were not reported in the original publication (included
secondary analyses: Body et al. [22] and Diel at al. [10];
excluded primary publications: Body et al. [23]a n dT r i p a t h y
et al. [24]).
Data extraction procedures
A total of 49 articles were selected for inclusion in the
current review. Table 1 presents the following information
on each study with a PRO assessing pain: citation, specific
bisphosphonate treatment, total sample size, description of
the pain PRO measure (as presented in the article itself), the
reference provided in each article for the pain PRO, and
information regarding whether the article specifies that the
measure is patient-reported. Table 2 presents similar infor-
mation for the subset of 19 studies that used PRO measures
to assess functional status or HRQL. Studies in Tables 1 and
2 are grouped based on the PRO measures that were
administered.
When analgesic use was assessed separately from pain,
we did not report this analgesic measure even if it was a
PRO. In some studies, however, analgesic use (which may
or may not have been patient reported) was one component
of an overall pain score which also incorporated a patient
rating of pain. In these situations, the overall pain assess-
ment is included in the tables, and the individual compo-
nents are listed (e.g., Berruti et al. [25], Jagdev et al. [26],
Mitsiades et al. [27], and Wang et al. [28]). Similarly,
functional status measures were occasionally used as one
component of a pain composite score. In these situations,
the functional status measure is listed as part of the com-
posite score in Table 1, even if the functional status measure
was not patient-reported.
Recent literature has distinguished among three types of
single-item measures of pain intensity [29–31]. A visual
analog scale (VAS) is a line, most frequently 100-mm long,
with each end of the line labeled with categorical descriptors
representing the minimum and maximum of pain intensity,
such as no pain to extreme pain. Patients are asked to place a
mark on the line that represents their pain intensity level
between the two extremes. A numerical rating scale (NRS)
consists of a range of numbers, usually 0 to 10, with anchors
at each end of the scale representing no pain and extreme
pain. Respondents are asked to choose the number that best
represents their level of pain intensity. A verbal rating scale
(VRS) consists of a list of descriptors or phrases that repre-
sent varying degrees of pain intensity. Each of these descrip-
tors often has a number associated with it (e.g., 00none, 10
mild pain, 20moderate pain, 30severe pain, and 40intoler-
able pain). In the articles reviewed for the current study,
single-item scales were frequently called a “VAS” even if
they were actually an NRS. In Table 1, single-item measures
have been categorized based on the definitions of VAS,
NRS, and VRS described here, regardless of the label used
by the authors. However, the descriptions of measures in the
fourth column of Table 1 use the exact wording from the
original sources, regardless of whether these labels were
used correctly. Thus, there are several measures described
by the original authors as a VAS, but categorized in the
current review as an NRS. In some cases, descriptions of
measures were not sufficiently clear to allow us to categorize
them with certainty. In these circumstances, we categorized
measures based on the terminology used by the authors. All
three of these single-item approaches can be used to assess
current pain as well as worst pain or average pain during a
specified recall period, such as 24 h or 7 days.
Results
Summary of studies in this review
A total of 49 studies were located that included patient-
reported measures of pain to assess outcomes of bisphospho-
nate treatment for bone metastases. Sample sizes of the indi-
vidual studies (excluding secondary and pooled analyses)
rangedfrom10to1,648patients.Themostcommontreatment
under investigation was zoledronic acid, which was examined
in22ofthestudies.Otherbisphosphonatetreatmentsincluded
clodronate (6 studies), etidronate (1 study), ibandronate (8
studies), and pamidronate (15 studies). Three of the
pamidronate studies included another bisphosphonate as
a treatment comparator. Trial designs varied across the
studies reviewed, with designs ranging from open-label,
single-center studies to randomized, double-blind, multi-
center controlled trials.
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Study using
measure
Treatment (n) Citation(s) given for
measure
Description of measures provided in each article Rater
Measure: Brief Pain Inventory (including studies that used at least one item of the BPI)
Berenson et
al. [33]
Zoledronic acid,
pamidronate (280)
Cleeland and Ryan
[32]
“At each study visit, patients were provided with a
questionnaire and asked to rate their pain since the
previous study visit on a scale from 1 to 10. The
questionnaire was part of a pain assessment tool,
the Brief Pain Inventory”
Patient
Carteni et al.
[76]
Zoledronic acid (312) No citation “Secondary efficacy variables included pain as
measured by the Brief Pain Inventory (BPI)
composite score. The BPI composite pain score was
defined as worst pain, average pain, and least pain
over the last 7 days and pain right now”
Not specified
Clemons et al.
[13]
Zoledronic acid (31) Cleeland and Ryan
[32]
“Palliative benefit was reflected through various
measures of pain (Brief Pain Inventory) and quality
of life (Functional Assessment of Cancer Therapy
[FACT])”
Not specified
Clemons et al.
[77]
Ibandronate (30) Cleeland and Ryan
[32]
“Palliative benefit was reflected through the Brief
Pain Inventory (BPI)”
Not specified
In addition to
correctly citing
Cleeland and Ryan
[32], Clemons et al.
[77] cite Cella et al.
[53], which appears
to be an incorrect
citation
Di Lorenzo et
al. [78]
Zoledronic acid (40) Cleeland and Ryan
[32]
“Pain response was measured via a self-administered
numeric rating scale (part of the Brief Pain Inven-
tory (BPI)). The BPI pain assessment is based on an
11-point scale (0–10), in which 0 represents no pain
and 10 represents severe pain. The values of “worst
pain,”“ least pain,”“ average pain of last few days,”
and “pain right now” were recorded every 4 weeks.
The primary assessment of pain was the difference
in the worst pain value every 4 weeks”
Patient
Hong et al.
[79]
Zoledronic acid (19) Cleeland and Ryan
[32]
“Bone pain was assessed using the brief pain
inventory (BPI) short form. A composite pain score
was used, calculated as a mean of the scores for
questions 3, 4, 5, and 6”
Not specified
Mystakidou et
al. [65]
Zoledronic acid (60) No citation “Each patient was asked to complete the Greek Brief
Pain Inventory (GBPI)”
Patient
No additional information was provided on the use of
this measure or its translation
Mystakidou et
al. [34]
Ibandronate (52) No citation “The Greek Brief Pain Inventory (G-BPI) was used to
measure metastatic bone pain. The selected G-BPI
items measured severity of pain by worst pain (item
3) and average pain (item 5), as well as interference
due to pain in the following activities: general ac-
tivity (item 9i), walking (item 9iii), working (item
9iv), and enjoyment of life (item 9vII). Scoring was
based on a ten-point scale (00no pain/does not
Not specified
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Study using
measure
Treatment (n) Citation(s) given for
measure
Description of measures provided in each article Rater
interfere with activity or 100unbearable pain/
completely interferes with activity)”
No additional information was provided on the
translation of this measure
Rosen et al.
[80]
Zoledronic acid,
pamidronate
(1,648)
Cleeland and Ryan
[32]
“The patient's pain was assessed using the Brief Pain
Inventory (BPI)”
Not specified
Rosen et al.
[81]
Zoledronic acid (773) Cleeland and Ryan
[32]
“Pain was assessed using the Brief Pain Inventory
(BPI) composite pain score”
Not specified
Article did not describe what was meant by the BPI
“composite score”
Saad et al.
[57]
Zoledronic acid (643) Cleeland and Ryan
[32]
“Quality-of-life parameters included a pain score
assessed with the Brief Pain Inventory (BPI)…The
BPI questionnaire was completed by the patient…
The pain score, as assessed on the BPI, was a
composite of four pain scores (worst pain, least
pain, average pain of the last 7 days, and pain right
now) and was the primary efficacy variable for the
quality-of-life assessments”
Patient
Small et al.
[21]
a
Pamidronate (378) Cleeland and Ryan
[32]
“Pain was measured via a self-administered numeric
rating scale (part of the Brief Pain Inventory (BPI)).
The BPI pain assessment is based on an 11-point
scale (0 to 10) on which 0 represents no pain to 10
represents pain as severe as can be imagined. The
“least,”“ average,” and “worst” pain since the last
visit were recorded at visits 1 through 11”
Patient
Wardley et al.
[51]
Zoledronic acid (101) Cleeland and Ryan
[32]
“Pain was assessed using the BPI, which measures
intensity of pain and interference of pain with daily
functioning. Patients rated their pain and the degree
to which pain limited their function at the time of
response to the questionnaire, as well as their worst,
least, and average pain over the previous 7 days”
Patient
Measure: Wisconsin Brief Pain Questionnaire (BPQ)
Berenson et
al. [36]
Zoledronic acid (44) Foley [82] “Pain scores were assessed at each patient visit, using
the Wisconsin Brief Pain Questionnaire, which
addresses relevant aspects of pain (i.e., history,
intensity, location, and quality)”
Not specified
Measure: McGill–Melzack Pain Questionnaire
Ernst et al.
[38]
Clodronate (209) Melzack [39] “Before randomization, patients completed the six-
point present pain intensity (PPI) scale of the
McGill–Melzack Pain Questionnaire. The pain
scale consists of a series of verbal descriptors: 00
no pain, 10mild pain, 20discomforting pain, 30
distressing pain, 40horrible pain, and 50excruci-
ating pain. Patients were explicitly asked to identify
the average pain level during the previous 24 h…
At each visit, they completed the PPI and HRQOL
questionnaires”
Patient
Tannock et al. [61]
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Study using
measure
Treatment (n) Citation(s) given for
measure
Description of measures provided in each article Rater
Measure: questionnaire from Guy's Hospital Assessment of Response Study
Berruti et al.
[25]
Pamidronate (35) Coleman [83]
(erroneously cited
by Berruti et al. as
Coleman (1993))
“Bone pain was evaluated by means of a validated
questionnaire according to Coleman. The items
included the assessment of performance status,
analgesic consumption, and mobility, resulting in a
pain score ranging from 0 to 16”
Not specified
For this measure,Berruti cites Coleman [83], whocites
a previous article by Coleman et al. [116]. Coleman
[83] presents the four items of this questionnaire,
assessing pain, analgesic use, mobility, and
performance status. According to Coleman [83],
scores can actually range from 0 to 20
Single-item: visual analog scale (VAS) described in terms of length
Addeo et al.
[84]
Zoledronic acid (16) Serlin et al. [85] “Pain assessments were conducted at baseline, before
each infusion, and at the final study visit using a
100-mm visual analog scale (VAS)”
Not specified
No additional information was provided on this
measure
Arican et al.
[86]
Clodronate (50) Sriwantanakul et al.
[87]
“The painful sites of all patients were determined in
the first examination, and bone pain was scored
according to ‘visual analogue scales’ (VAS). Pain
scoring was done using a 10-cm length line with 1-
cm breaks with pain level increasing from 0 to 10 (o
for no pain and 10 for heavy pain)”
Not specified
Hultborn et al.
[88]
Pamidronate (404) No citation “Every third month, the patients filled in a pain score
questionnaire including the following visual analog
scales (100-mm lines, least symptoms to the left):
(a) pain intensity, (b) frequency of pain, (c)
impairment of physical ability due to pain, (d)
impairment of sleep due to pain, (e) pain regression
or progression since last visit, (f) global judgment
of improvement or deterioration”
Patient
Vogel et al.
[89]
Zoledronic acid (638) No citation “Pain assessments were conducted at baseline, before
each infusion, and at the final study visit using a
100-mm visual analog scale (VAS)”
Not specified
No additional information was provided on this
measure
Single-item: unspecified scale called a “visual analog scale”
Fulfaro et al.
[90]
Zoledronic acid (18) Serlin et al. [85] “Pain was assessed by visual analogue scale (VAS)
numeric scale”
Not specified
Article did not provide additional details on this
measure
Santangelo et
al. [91]
Clodronate (35) Kaplan et al. [92] “The visual analog scale (VAS) for pain relief…[was]
evaluated after 1, 3, and 6 months of treatment”
Not specified
Article did not provide additional details on this
measure
Single-item: 0 to 10 numerical rating scale (NRS)
Facchini et al.
[56]
Zoledronic acid (60) No citation “The impact of the therapy on bone pain was
evaluated with bone pain index. Severity of pain
Not specified
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Study using
measure
Treatment (n) Citation(s) given for
measure
Description of measures provided in each article Rater
was assessed with a single-item continuous visual
analog scale that asks the patient to place an “x” on
a 0 to 10 scale, where 00no pain, 0–30mild, 3–60
moderate, 6–90severe, and 9–100intolerable”
Heidenreich et
al. [93]
Clodronate (85) No citation “Bone pain severity was assessed by the patients using
a visual analogue scale from 00no to 100severe
pain…Atthevisits,theyassessedtheseverityofbone
pain using a visual analogue scale of 0 to 10”
Patient
Heidenreich et
al. [94]
Ibandronate (25) No citation “Severity of bone pain was assessed by the patients
usingavisualanaloguescale(VAS)extendingfrom0
(no pain) to 10 (severe pain)…To evaluate the
analgesic effect of ibandronate, patients had to assess
the severity of bone pain using a VAS from 0 to 10”
Patient
Leto et al. [95] Zoledronic acid (30) Serlin et al. [85] “The symptomatic response to ZA treatment was
assessed according to Serlin et al. by using a visual
analog scale score (VAS), which ranged from 0 (no
pain at all) to 10 (unbearable pain)”
Not specified
Mañas et al.
[50]
Zoledronic acid (139) No citation “The main study variables were pain and quality of
life, reported by the patients and measured using
the following parameters: visual analogue pain
scale (vas)—a horizontal scale marked in
millimeters, ranging from 0 ‘no pain’ to 10
‘agonizing.’ The VAS was measured on each visit
with the patient supine, seated, and standing”
Patient
Mancini et al.
[62]
Ibandronate (18) Bruera et al. [96] “Bone pain was assessed using a visual analog scale
from 0 (no pain) to 10 (maximum pain)”
Not specified
Jacox et al. [97]
Rodrigues et
al. [98]
Clodronate (58) No citation “All patients were asked to estimate their pain on a
visual pain scale from 0 to 10 (no pain to very
strong pain) at every visit”
Patient
Storto et al.
[99]
Zoledronic acid (49) Serafini et al. [100] “Bone pain…[was] documented in diaries…In the
diary, the patients specified the level and extent of
bone pain in 12 body regions (head and neck,
scapular crawler bone, left arm, left ribs, right arm,
right ribs, upper spine, lower spine, left hip, right
hip, left leg, right leg) according to a visual
analogue scale (VAS) rating from 0 (no pain, no
discomfort) to 10 (pain, worst discomfort)”
Patient
Vassiliou et al.
[101]
Ibandronate (45) No citation “Bone pain in the specified treatment site was
evaluated by patients using a scale from 0 to 10 (00
no pain and 100worst possible pain)”
Patient
Vassiliou et al.
[102]
Ibandronate (70) No citation “Bone pain evaluation in specific anatomical regions
that were to be irradiated was carried out by using a
visual analog scale rated from 0 to 10 (00no pain or
100worst possible pain)”
Not specified
Single-item: 1 to 5 numerical rating scale (NRS)
Efstathiou et
al. [103]
Zoledronic acid (54) No citation “The pain score was measured using a visual
analogue scale from 1 to 5”
Not specified
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Study using
measure
Treatment (n) Citation(s) given for
measure
Description of measures provided in each article Rater
Single-item: verbal rating scale (VRS)
Body et al.
[22]
b
Ibandronate (564) Coleman [104] “The secondary endpoint measures of bone pain
scores and analgesic consumption were evaluated at
each study assessment visit…using a patient-rated
scoring system. Briefly, patients were asked to
score their average bone pain over the last week
using a five-point scale: 00none, 10mild, 20
moderate, 30severe, or 40intolerable”
Patient
Diel et al.
[10]
c
Ibandronate (466) Coleman [104] “The assessment of bone pain was carried out at each
study visit using the patient-rated scoring system
for pain and analgesic use previously described.
Patients were asked to describe, on average, how
severe their bone pain had been over the last week
and to score it on the scale of 0 (none), 1 (mild), 2
(moderate), 3 (severe), or 4 (intolerable)”
Patient
Groff et al.
[105]
Pamidronate (200) No citation “The following parameters were also assessed: pain
intensity by means of a Likert verbal scale (no pain0
0, a little033.3, much066.6, or very much0100)”
Patient
Martinetti et
al. [106]
Pamidronate (28) No citation “The following parameters were assessed for each
patient: pain intensity by means of a Likert verbal
scale (no pain, a little, much, or very much)”
Patient
Martinetti et
al. [107]
Pamidronate (42) No citation “The following are clinical parameters assessed for
each patient: pain intensity [using the Likert verbal
scale (no pain, a little, much, or very much)]”
Patient
Mitsiades et
al. [27]
Zoledronic acid (38) No citation “Evaluations of symptomatic improvement and
quality of life were performed using…a bone pain
score(PS),whichprovides,onasix-pointscale(from
0to5),thecompositeexpressionofpainintensityand
analgesic requirements (type and quantity of analge-
sics consumed; i.e., 00lack of bone pain without
analgesics; 10occasional mild pain, not necessitating
use of analgesics; 20constant moderate pain, neces-
sitatinguseofnon-opiateanalgesics;30constantpain
(severe), necessitating constant consumption of
common analgesics; 40severe constant pain, requir-
ing use of opiate analgesics; and 50severe pain re-
fractory even to opiate analgesic)”
Not specified
Ripamonti et
al. [108]
Zoledronic acid (48) No citation Pain intensity at rest and movement-related pain was
rated by the patient on a six-level verbal rating scale
(VRS) where 00none, 10very mild, 20mild, 30
moderate, 40severe, and 50very severe pain.
Patients were asked two questions: ‘How much was
the intensity of pain at rest during the past week?’
and ‘How much was the intensity of pain induced
by movement during the past week?’ Moreover, we
explained to patients that we considered average
pain”
Patient
This article is unclear regarding whether rest and
movement were integrated into a single rating or
assessed as two separate ratings. Authors state that
they “considered average pain,” although “average
pain” is not defined
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Study using
measure
Treatment (n) Citation(s) given for
measure
Description of measures provided in each article Rater
Pain scores derived by multiplying pain severity and pain frequency
Berenson et
al. [109]
Zoledronic acid (59) Tong et al. [110] “Assessment of pain and analgesic use was conducted
using previously described methods. Pain scores
reflect the patient's perception of pain during the
weekbeforeeachstudyvisit.Theseverityofpainwas
rated on a scale of 0 (no pain) to 3 (severe pain). The
frequencyofpain was ratedona scaleof0 (none) to 3
(constant). Pain score was calculated by multiplying
the severity by the frequency”
Patient
Kouloulias et
al. [111]
Pamidronate (18) Theriault et al. [41] “The bone pain scores were calculated by
multiplying the pain severity (0 to 3) by the pain
frequency (0 to 3)”
Not specified
Kouloulias et
al. [112]
Pamidronate (33) Hillner et al. [113] “The bone pain scores were calculated by
multiplying the pain severity (0–3) by the pain
frequency (0–3)”
Not specified
Theriault et al. [41]
Kouloulias et
al. [114]
Pamidronate (103) Theriault et al. [41] “Bone pain was evaluated using a scoring system that
quantified both the severity and frequency of bone
pain. Bone pain scores were calculated by
multiplying the score for pain severity (graded from
0 to 3) by the score for pain frequency (graded from
0 to 3). A score of 0 indicates no bone pain, and a
score of 9 indicates constant, severe bone pain. A
decrease in bone pain represented an improvement”
Not specified
Lipton et al.
[20]
d
Pamidronate (754) Tong et al. [110] “Bone pain was evaluated using a scoring system that
quantified both the severity and frequency of bone
pain. The bone pain score was determined by
multiplying the bone pain severity score by the
bone pain frequency score”
Not specified
Composite scores combining bone pain with other constructs
Jagdev et al.
[26]
Clodronate,
pamidronate (51)
Purohit et al. [115] “Analgesic consumption, ECOG performance status
and pain intensity, using categorical assessments,
werealsorecordedandamalgamatedintoapainscore
as described previously…Patients were requested to
completethepainquestionnaireateachvisittorecord
pain intensity, analgesic consumption, and
performance status. These three parameters were
combined to give an overall pain score”
Patient
Coleman et al. [116]
Vitale et al.
[42]
Pamidronate (10) No citation “To assess symptomatic response, patients were asked
to record at baseline and quarterly the average
intensity of pain during the previous week by using a
100-mm visual analogue scale (VAS), where 0 stood
for no pain and 100 for extremely severe pain (Hus-
kisson scale)…We also calculated the trial outcome
index (TOI), by adding the functional to the physical
domain score [from the FACT-G], and a pain score
was obtained by adding TOI to 100-VAS”
Patient
Wang et al.
[28]
Pamidronate (18) Hortobagyi et al.
[117]
“Using previously validated methods, intensity of
bone pain was graded as follows: mild01 point,
moderate02 points, severe03 points, and
unbearable04 points and frequency as occasional0
1 point, intermittent02 points, frequent03 points,
and constant04 points for each skeletal segment. A
regional pain index (intensity × frequency) was
Not specified
Price et al. [118]
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All 49 studies are listed in Table 1, grouped according to 12
categories of pain measures. The first four measures are
multi-item scales: (1) the Brief Pain Inventory (BPI), (2)
Wisconsin Brief Pain Questionnaire (BPQ), (3) McGill–
Melzack Pain Questionnaire, and (4) a questionnaire from
Guy's Hospital Assessment of Response Study. The next
four categories of measures are reported by the original
authors as “visual analogue scales”: (5) VASs with a spec-
ified length, (6) ten-point VASs, (7) five-point VASs, and (8)
unspecified VASs. Then, four additional groups of measures
are presented:(9) single-item scales that are not labeled by the
original authors as VASs, (10) scores derived by multiplying
pain severity and pain frequency, (11) composite scores in-
volving combinations of bone pain with other constructs, and
(12) a face scale. Table 1 includes descriptions of each mea-
sure, quoted from the articles included in the current review.
The BPI was the most common formally developed and
named instrument used for assessing pain. This question-
naire was developed by the Pain Research Group of the
WHO Collaborating Center for Symptom Evaluation in
Cancer Care [32]. The original development article states
that “depending on the patient, it can be self-administered or
used in a clinical interview, [and] the form of administration
has little effect on the outcome.” The BPI was adapted from
the Wisconsin Brief Pain Questionnaire for use with cancer
patients to assess intensity and interference of pain. Both
short and long form versions of the BPI include questions
about pain location, severity, relief, and interference. The
four pain severity items ask patients to rate their worst, least,
average, and current pain (i.e., “pain right now”) over the past
week (in the long form of the BPI) or 24 h (in the short form)
using a 0–10 NRS (00no pain or 100pain as bad as you can
imagine). Theseven paininterferenceitems ask the patientsto
rate the degree to which pain limits their functions using a 0–
10 NRS (00no interference or 100interferes completely). A
total of 13 studies used part or all of the BPI, including 11
studies using an English version and two studies using the
Greek version. Among the 11 English studies, there was
variation in the items that were used. For example, some
studies focused on a composite of the four pain scores (worst,
least, average, and current pain), while other studies appear to
have used a smaller subset of these items, but this information
Table 1 (continued)
Study using
measure
Treatment (n) Citation(s) given for
measure
Description of measures provided in each article Rater
then calculated for each skeletal segment. Pain
assessment also included information about the
dosage and type of analgesic drugs administered, as
well as an evaluation of the patient's general state of
health and physical activity, according to the
Karnofsky index”
Measure: face scale
Iwamoto et al.
[46]
Etidronate (30) Lorish and Maisiak
[119]
“Bone pain was evaluated quantitatively by assessing
the mood of patients according to a face scale. The
face scale contains ten drawings of a single face,
arranged in serial order in rows, with each face
depicting a slightlydifferent mood.Subtle changesin
the eyes, eyebrows, and mouth are used to represent
slightlydifferentlevelsofmood.Theyarearrangedin
decreasingorderofmoodandnumbered1–10,with1
representing the most positive mood and 10
representing the most negative mood. As the
examiner pointed at the faces, the following
instructions were given to each patient: ‘The faces
below go from painless at the top to very painful at
the bottom. Point to the face that best shows the way
you have felt local bone pain today.’ The validity and
reliability of the face scale have already been
demonstrated, although pain is a subjective symptom
which is relatively difficult to evaluate”
Patient
aPooled analysis of two randomized, multi-center, double-blind, placebo-controlled studies (trial INT-05 and trial CGP-032)
bSecondary analysis of two double-blind, placebo-controlled multicenter, parallel-group studies (trials MF 4414 and MF 4434)
cSecondary efficacy results from a randomized, double-blind, placebo-controlled, parallel group, phase III trial (Body et al. [23])
dSecondary analysis of two randomized, double-blind, placebo-controlled, multi-center studies (Theriault et al. [41] and Hortobagyi et al. [120])
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Study using
measure
Treatment (n) Citation(s) given
for measure
Description of measures provided in each article Rater
Measure: European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30)
Body et al. [22]
a Ibandronate
(564)
Aaronson et al.
[48]
“The secondary endpoint parameter of quality of life was
assessed…using the European Organisation for Research and
Treatment of Cancer Quality of Life questionnaire-C30 (EORTC
QLQ-C30). The 30-item questionnaire includes five functional
scales (physical functioning, role functioning [work and house-
hold], cognitive functioning, emotional functioning, and social
functioning). Higher scores on the functional scales represent a
better level of functioning. These scores are combined to produce
a global quality of life score, on a scale from 0 to 100 (higher
scores indicate better quality of life)”
Not specified
Diel et al. [10]
b Ibandronate
(466)
Aaronson et al.
[48]
“Quality of life was assessed using a validated quality of life scale
(QLQ-C30) produced for the European Organisation for Research
and Treatment of Cancer (EORTC). This is a 30-item question-
naire incorporating five functional scales (physical functioning,
role functioning [work and household], cognitive functioning,
emotional functioning, and social functioning), three symptom
scales (fatigue, pain, and nausea and vomiting), and a global
health scale. The remaining items assess additional symptoms
commonly reported by cancer patients (dyspnea, appetite loss,
sleep disturbance, constipation, and diarrhea), as well as the
perceived financial difficulties underlying the disease and its
treatment”
Patient
c
Kouloulias et al.
[112]
Pamidronate (33) Aaronson et al.
[48]
“The assessment of QOL was…performed using the European
Organization for Research and Treatment of Cancer (EORTC)
Core Quality of Life Questionnaire (QLQ-C30, version 3)…All
scales and items of the EORTC QLQ-C30 range in score from 0 to
100…The QLQ-C30 instrument was scored according to the
EORTC procedures using the EORTC QLQ-C30 scoring manual
(third edition, January 2001). The tool used was a valid transla-
tion, undergoing the EORTC formal transnational procedure”
Patient
Mañas et al. [50] Zoledronic acid
(139)
No citation “The main study variables were pain and quality of life, reported by
the patients and measured using the following parameters: quality
of life—The EORTC QLQ-30 questionnaire was administered,
divided into three parts: part one includes five yes/no questions
referring to daily activities; part two includes 21 questions refer-
ring to the patient's daily symptoms with responses ranging from
1 to 4; and part three includes two questions referring to the
patient's general health, with responses ranging from 1 to 7”
Patient
Vassiliou et al.
[101]
Ibandronate (45) Fayers et al.
[121]
“Physical functioning was assessed using the European
Organization for Research and Treatment of Cancer QLQ-C30
scale, graded from 0 to 100”
Not specified
Vassiliou et al.
[102]
Ibandronate (70) Fayers et al.
[121]
“QOL was evaluated using the European Organization for Research
and Treatment of Cancer QOL questionnaire (EORTC QLQ-
C30). EORTC-C30 is composed of five functional scales, one
global scale, and three symptom scales, graded from 0 to 100. For
the functional and global scale, a higher score represents a better
level of functioning. In the current study, physical functioning
was evaluated and analyzed”
Not specified
Wardley et al.
[51]
Zoledronic acid
(101)
Aaronson et al.
[48]
“Quality of life was measured using the European Organisation for
Research and Treatment of Cancer (Quality of Life Core
Questionnaire 30 (EORTC QLQ-C30)…The EORTC QLQ-C30
questionnaire incorporates nine multi-item scales: five functional
Not specified
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Study using
measure
Treatment (n) Citation(s) given
for measure
Description of measures provided in each article Rater
scales (physical, role (work and household activities), cognitive,
emotional, and social), three symptom scales (fatigue, pain, and
nausea and vomiting), and a global health and quality-of-life
scale”
Measure: European Organization for Research and Treatment of Cancer-Breast Cancer Module (EORTC QLQ-BR23)
Wardley et al.
[51]
Zoledronic acid
(101)
Sprangers et al.
[52]
“Quality of life was measured using the European Organisation for
Research and Treatment of Cancer (Quality of Life Core
Questionnaire 30 (EORTC QLQ-C30) and the corresponding
disease-specific BR23 breast cancer module…The BR23 breast
cancer module consists of 23 items covering symptoms and side
effects related to different treatment modalities, body image,
sexuality, and future perspective”
Not specified
Measure: Functional Assessment of Cancer Therapy-General (FACT-G)
Addeo et al. [84] Zoledronic acid
(86)
Cella et al. [53] “QoL was assessed at baseline and before infusions at examinations
3 and 6 using the Functional Assessment of Cancer Therapy-
General (FACT-G) questionnaire”
Not specified
No additional information was provided on this measure
Carteni et al. [76] Zoledronic acid
(312)
No citation “Other variables included…QOL as assessed by the Functional
Assessment of Cancer Therapy-General (FACT-G) questionnaire”
Not specified
No additional information was provided on this measure
Facchini et al.
[56]
Zoledronic acid
(60)
Cella et al. [53] “Patients completed the Functional Assessment of Cancer Therapy-
General questionnaire (FACT-G, version 4). FACT-G is a multi-
dimensional questionnaire developed and validated in cancer
patients to evaluate the changes in the four main domains of the
quality of life: physical well-being (seven items), social/family
well-being (seven items), emotional well-being (six items), and
functional well-being (seven items). Patients scored each item on
afive-pointordinal scale rangeranging from0to4(00n o ta ta l l ,10
a little bit, 20somewhat, 30quite a bit, or 40very much) during the
previous 7 days….We also calculated a trial outcome index (TOI),
by adding the functional to the physical domain score”
Patient
The trial outcome index (TOI) was calculated by adding the
functional and physical domain scores of the FACT-G, which is
inconsistent with instructions from the instrument developers
Hong et al. [79] Zoledronic acid
(19)
Cella et al. [53] “The Functional Assessment of Cancer Therapy-General (FACT-G)
questionnaire was administered at screening, at the fourth infusion
of zoledronic acid and at the final visit. Quality of life scores
representing four questionnaire subscales were evaluated, as well
as changes in scores for each subscale…The higher FACT-G
scores the better the patient's quality of life”
Patient
d
Mystakidou et al.
[34]
Ibandronate (52) No citation “QoL was determined using the functional assessment of cancer
therapy-general (FACT-G; total physical and total function well-
being scales). The physical and functional QoL subscales both
consisted of seven questions; each question was measured on a
four-point scale (00no QoL or 40very high QoL). The sum of
these seven questions in each subscale determined the total
physical and functional QoL score. Question 8 of each subscale
(e.g., physical 8 and function 8) measured how much the physical
and functional well-being of the patient affects his/her QoL on a
ten-point scale (00not at all or 100very much)”
Not specified
Rosen et al. [81] Zoledronic acid
(773)
No citation “Quality of life was measuring using the Functional Assessment of
Cancer Therapy-General (FACT-G) instrument”
Not specified
668 Support Care Cancer (2012) 20:657–677was not always presented clearly. Seven of the studies using
the BPI did not specify that the instrument was completed by
patients, and some studies erroneously described the response
options as “1t o1 0 ” or “ten-point scale” [33, 34], when there
Table 2 (continued)
Study using
measure
Treatment (n) Citation(s) given
for measure
Description of measures provided in each article Rater
Saad et al. [57] Zoledronic acid
(643)
Cella et al. [53] “Quality-of-life parameters included…the Functional Assessment
of Cancer Therapy-General (FACT-G), version 4…The FACT-G
[was] completed by the patient”
Patient
Vitale et al. [42] Pamidronate (10) Cella et al. [53] “Patients completed the Functional Assessment of Cancer Therapy-
General questionnaire (FACT-G, version 4). FACT-G is a multi-
dimensional questionnaire developed and validated in cancer
patients to evaluate the changes in the four main domains of the
quality of life: physical well-being (seven items), social/family
well-being (seven items), emotional well-being (six items), and
functional well-being (seven items). Patients scored each item on
a five-point ordinal scale range ranging from 0 to 4 (00not at all,
10a little bit, 20somewhat, 30quite a bit, or 40very much)
during the previous 7 days…We also calculated the trial outcome
index (TOI) by adding the functional to the physical domain score
[of the FACT-G]”
Patient
This study calculated the TOI by adding only the functional and
physical domain scores from the FACT-G. The authors did not
appear to use a third subscale (“additional concerns”) as suggested
by the instrument developers
Vogel et al. [89] Zoledronic acid
(638)
Cella et al. [53] “QOL was assessed at baseline and before infusions at visits 2 and 6
using the Functional Assessment of Cancer Therapy-General
(FACT-G) questionnaire”
Not specified
Measure: EuroQol EQ-5D
Saad et al. [57]] Zoledronic acid
(643)
EuroQol Group
[59]
“Quality-of-life parameters included…the EURO Quality of Life
EQ-5D (EURO QOL)…The EURO QOL [was] completed by the
patient”
Patient
Measure: Prostate Cancer-Specific Quality of Life Instrument (PROSQOLI)
Ernst et al. [38] Clodronate (209) Stockler et al.
[60]
“HRQOL was assessed by the Prostate Cancer-Specific Quality-of-
Life Instrument (PROSQOLI). The instrument, completed by the
patientsateachvisit,usedaseriesofninelinearanalogscalesrelated
to pain, physical activity, fatigue, appetite, constipation, passing
urine, family/marriage relationships, mood, and overall well-being”
Patient
Measure: Edmonton Symptom Assessment System (ESAS)
Mancini et al.
[62]
Ibandronate (18) Bruera et al. [63] “Patient QOL was assessed daily using the well-being item scale
from the Edmonton Symptom Assessment System (ESAS). The
item is scored on a ten-point scale from 0 (best feeling of well-
being) to 10 (worst possible feeling of well-being)”
Not specified
Measure: Linear Analog Scale Assessment/Linear Analog Self-Assessment (LASA)
Mystakidou et al.
[65]
Zoledronic acid
(60)
No citation “Each patient was asked to complete…the linear analog scale
assessment (LASA) of quality of life at baseline and at specific
time points during the study”
Patient
No additional details were provided on the type of LASA used
aSecondary analysis of two double-blind, placebo-controlled multicenter, parallel-group studies (trials MF 4414 and MF 4434)
bSecondary efficacy results from a randomized, double-blind, placebo-controlled, parallel group, phase III trial (Body et al. [23])
cWhile the authors did not specify whether it was clinician-rated or patient-reported, we assumed it was patient-reported because it was completed
“1 day before each of the appropriate study visits”
dSince the questionnaire “was administered,” we assumed this to be a patient-reported measure
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addition, one of the studies appears to have used the worst
pain item as a single-item NRS measure [33]. Furthermore, it
islikely thatmostorall ofthese studieswereusing items from
the most recent version of the BPI, which the instrument
developer calls the short form [35]. However, few of the
studies specified which version of the instrument was used.
Three additional multi-item scales were each used in only
one study. The Wisconsin Brief Pain Questionnaire was
administered in a study by Berenson et al. [36], although
minimal details were provided regarding the characteristics
or administration of the instrument. This measure was
designed to be a self-administered assessment of pain asso-
ciated with cancer and other diseases [37]. It assesses con-
structs similar to those subsequently included on the BPI, as
described above. The McGill–Melzack Pain Questionnaire
was used in a study by Ernst et al. [38], which admin-
istered only the six-point Present Pain Intensity scale of
this instrument, ranging from no pain to excruciating
pain. The study identified in the current review did not
include other items of this instrument, such as those for
which patients are instructed to select words that best
describe their pain experience [39, 40]. Finally, Berruti
et al. [25] administered a brief unnamed questionnaire,
but provided minimal description and an incorrect cita-
tion as explained in Table 1.
The most common approach for assessing pain intensity,
which was used in 24 studies, was to administer a single-
item scale such as VAS, NRS, and VRS measures (these
three types of single-item measures are defined above in the
“Methods” section). Most articles did not explicitly state
that these scales were completed by the patient, but it is
likely that they were patient-completed in all cases. There
was substantial variation in descriptions and citations of
these single items. In four studies, the VAS was described
in terms of a specific length (e.g., 10 cm or 100 mm), while
the most frequently used single-item was a 0–10 NRS. Two
studies mentioned that a VAS was used to assess pain, but
did not provide any description of the VAS. Less than half of
the studies using a single-item provided a citation for the
scale, and there was great variation in the citations among
the articles that did provide a reference. One of the single-
item scales combined two constructs, requiring patients to
simultaneously rate pain and analgesic use [27]. In sum,
although it was common to use a single-item for pain
assessment, there was substantial variation in the type of
single-item used, strategy for implementation, citation, and
clarity with which the measure was described. Furthermore,
no studies mentioned that the single-item measure was
validated for use in the target population.
Several studies derived a single pain score from a com-
bination of multiple scores. For example, five studies in-
cluded a pain score that was computed by multiplying
severity and frequency of pain. Three of these five studies
cite a pamidronate clinical trial published by Theriault et al.
[41] when discussing this approach. However, Theriault and
colleagues do not provide a citation or details for the origin
of this scoring system. Two additional studies included a
pain rating as one component of a composite score that also
incorporated analgesic consumption and performance status
or overall health [26, 28]. In addition, one study conducted
by Viatale et al. [42] computed a pain score by adding scores
from a 100-mm VAS for pain to a Trial Outcome Index,
which was the “sum of the physical and functional domains
of the FACT-G.” In this study, the authors referred to the
VAS as the “Huskisson” VAS, but did not provide a citation
for this VAS. Huskisson published several articles on the
measurement of pain using visual and graphic methods
[43–45]. His publications suggest that VASs “provide the
patients with a robust, sensitive, reproducible method of
expressing pain severity” [44]. For the current review, we
were unable to locate a specific VAS called the “Huskisson
VAS.” It is possible that Vitale et al. [42] developed a new
VAS according to Huskisson's principles and called it the
Huskisson VAS.
Finally, one study used an approach called a “face scale,”
which involved assessing patients' bone pain based on
choosing a face that most reflected their current mood
[46]. This face scale appears to be similar to items from
the Functional Health Assessment Charts used in the Dart-
mouth Primary Care Cooperation Project (COOP Project)
[47].
HRQL and functional status measures (19 studies)
Of the 49 studies using a PRO measure to assess pain, 19
studies included at least one PRO assessing functional status
or HRQL. These studies are listed in Table 2, grouped
according to the seven measures used: (1) European Orga-
nization for Research and Treatment of Cancer QLQ-C30
(EORTC QLQ-C30), (2) EORTC Breast Cancer Module
(QLQ-BR23), (3) Functional Assessment of Cancer
Therapy-General (FACT-G), (4) EuroQol EQ-5D (EQ-5D),
(5) Prostate Cancer-Specific Quality of Life Instrument
(PROSQOLI), (6) the Edmonton Symptom Assessment
System (ESAS), and (7) linear analog scale assessment of
quality of life. The EORTC QLQ-C30 and the FACT-G
were the most commonly used HRQL and functional status
measures, while the other five measures were each used in
only a single study. Table 2 includes descriptions of each
measure, quoted from the articles included in the current
review.
Seven studies administered the EORTC QLQ-C30,
which was developed to evaluate the quality of life of
patients participating in international oncology trials [48].
The EORTC QLQ-C30 was designed to be relevant to a
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with separate questionnaire modules designed for specific
cancer types or treatments (although only one study in the
current review administered one of these supplemental mod-
ules, discussed below). This measure includes 30 items
which contribute to five functional scales (physical, role,
cognitive, emotional, and social), three symptom scales
(fatigue, pain, and nausea and vomiting), a global health
scale, and a quality of life scale. In the most recent version
(version 3.0), the first 28 items are rated on a four-point
Likert scale (10not at all or 40very much), and the last two
items are rated on a seven-point Likert scale (10very poor
or 70excellent) [49]. Among the seven studies administer-
ing the EORTC QLQ-C30, there were differences in how
the questionnaire was used. Two studies analyzed only the
physical functioning domain of this questionnaire, while
another study described only the functional scales without
indicating whether the other scales were also administered.
The study by Mañas et al. [50] does not specify which
version of the EORTC QLQ-C30 was used, but describes
as e r i e so f“yes/no questions,” which is suggestive of version
1.0 before response options were modified to the four-point
Likert scales used in subsequent versions. Six of the seven
studies did not specify which version was administered, and
fourofthestudiesdidnotmentionwhethertheinstrumentwas
completed by patients.
In addition to administering the EORTC QLQ-C30,
Wardley et al. [51] assessed quality of life using the Breast
Cancer Module (QLQ-BR23). This condition-specific ques-
tionnaire was developed by the EORTC Study Group to be
used in conjunction with the EORTC QLQ-C30. Developed
according to the EORTC guidelines for module develop-
ment, the QLQ-BR23 focuses on aspects of quality of life
specifically related to breast cancer with 23 items assessing
treatment modalities, body image, sexuality, and future per-
spective [52].
Nine studies administered the FACT-G, which was de-
veloped by Cella et al. [53] as a quality of life questionnaire
for use in patients receiving cancer treatment. This ques-
tionnaire is part of the Functional Assessment of Chronic
Illness and Therapy measurement system, which is a collec-
tion of HRQL questionnaires focusing on chronic illnesses
[54]. Version 4 of the FACT-G (the most recent version)
contains 27 items, which comprise four subscales (physical,
social/family, emotional, and functional). Each item is rated
on a five-point Likert scale (00not at all or 40very much)
[53, 55]. Among the nine studies that administered the
FACT-G, there was some variation in the way the subscales
were used. Two studies indicated that only the functional
and physical well-being subscales were analyzed. In one of
these studies, Facchini et al. [56] calculated a Trial Outcome
Index (TOI) by summing only the functional and physical
subscales. This approach to calculating the TOI is not
entirely consistent with recommendations from the instru-
ment developers. The developers specified that the TOI can
be calculated for use as an endpoint in clinical trials based
on these two subscales as well as an “additional concerns”
subscale from one of the Functional Assessment of Chronic
Illness Therapy (FACIT) disease-, treatment-, or condition-
specific scales [55]. In the other study, Mystakidou et al.
[34] stated that the functional and physical subscales were
used to calculate a “total physical and functional QOL
score,” which also appears to be inconsistent with instruc-
tions from the instrument developers. Only three of the nine
studies specified the version of the FACT-G that was used,
and five studies did not specify that this questionnaire was
completed by patients.
The large zoledronic acid trial published by Saad et al.
[57] was the only study in this review to administer the EQ-
5D. The EQ-5D is a generic preference-based health status
instrument used in health economic relations. Patients report
their functioning in five dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression
[58, 59]. Responses to these five items are used to derive
the EQ-5D index score, which represents overall health.
After completing the five dimension items, patients com-
plete the EQ-5D VAS, on which they rate their current
health on a scale ranging from 0 (worst imaginable health
state) to 100 (best imaginable health state).
Ernst et al. [38] used the nine-item PROSQOLI question-
naire, which was derived by Stockler et al. [60]f r o ma
longer version originally developed by Tannock et al. [61].
The original version was designed to assess the effects of
systemic treatments in men with advanced hormone-
resistant prostate cancer. The Stockler version consists of
nine linear analog self-assessment scales assessing pain and
quality of life, the six-point Present Pain Intensity (PPI)
verbal scale from the McGill Pain Questionnaire, and an
analgesic score. These nine linear scales are each 10-cm
long, and the score is measured in millimeters with 100
representing best function or quality of life.
The small ibandronate trial published by Mancini et al.
[62] was the only study in this review to use an item from
the ESAS, which was developed and validated as a self-
report symptom intensity measure for patients with cancer
[63, 64]. The ESAS originally consisted of eight 100-mm
VASs for pain, activity, nausea, depression, anxiety, drows-
iness, appetite, and sensation of well-being. A ninth VAS for
shortness of breath was subsequently added, and some ver-
sions also include an additional blank VAS for a symptom
that can be added by the patient. The Mancini et al. [62]
study only used the well-being item of the ESAS.
Lastly, one study administered a measure described as a
“linear analog scale assessment (LASA) of quality of life”
[65]. Linear analog self-assessments, also referred to in the
literature as LASAs or linear analog scale assessments, use
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are asked to mark their current state along the line, and
scores are measured in distance (e.g., centimeters or milli-
meters) to this mark from point 0. Mystakidou et al. [65]d o
not provide a citation or additional details for this measure.
Discussion
A diverse range of PRO measures has been used to assess
pain and its impact among patients with bone metastases,
with little consistency in measurement approach across
studies. Based on this review, there appears to be no con-
sensus on a strategy for assessing pain in patients with bone
metastases. Furthermore, presentation of measures in the
published articles often lacked clear description, information
on measurement properties, citations, or a consistent ap-
proach to naming the instruments and method of adminis-
tration. Given this lack of measurement consistency and
clarity, it is difficult to directly compare findings across
studies in order to understand the relative potential for pain
relief offered by the various bisphosphonates and other
treatments. Comparisons across studies using different out-
come measures would require calculating effect sizes for
each measure [67], an approach which is based on the
assumption that different measures are truly assessing the
same construct. The lack of measurement consistency across
clinical trials is similar to the inconsistent methods clinicians
use to assess pain in clinical settings, as reported by patients
in a recent large international survey [68].
The results of this review raise questions regarding in-
strument development and validation. It is frequently rec-
ommended that PRO instruments be psychometrically
evaluated in the population under investigation [69, 70].
However, none of the pain measures reviewed for this study
(Table 1) were developed specifically for patients with bone
metastases, and none of the articles mentioned instrument
validation conducted within this population. Similarly, none
of the HRQL/function measures (Table 2) are specifically
targeted towards this population. As a result, it is not possi-
ble to know whether these instruments are capturing the
aspects of pain and its impact that are most relevant and
important to patients with bone metastases. Furthermore, the
measurement approaches in these studies frequently do not
meet the standards for PRO development and validation set
forth in the FDA guidance document [15].
A first step toward improving measurement of pain in
patients with bone metastases would be to establish the
content validity of frequently used instruments from the
patient's perspective [71, 72]. This process would require
qualitative interviews in which patients are asked about the
relevance of the items to their condition, as well as the
clarity and comprehensiveness of each item. These
interviews could help determine whether single items,
which are commonly used, are sufficient for capturing pain
among these patients. Although there is support for reliabil-
ity and validity of single-item pain intensity measures, pain
is known to have qualities beyond the single dimension of
intensity, with descriptors such as tingly, deep, sharp, or dull
[31, 73]. Consequently, a thorough assessment of pain as-
sociated with bone metastases may require a multidimen-
sional instrument assessing the range, types, frequency,
duration, location, and impact of bone pain. It is possible
that the pattern of a patient's ratings across all of these
dimensions could influence treatment decisions.
Several PRO instruments have recently been developed
specifically for use in patients with bone metastases. For
example, a bone metastases module has been drafted to
supplement the European Organization for Research and
Treatment of Cancer (EORTC) Core Questionnaire [6]. This
new module includes 22 items assessing symptoms, func-
tional interference, and psychosocial domains. Furthermore,
the FACIT system now has a questionnaire called the Func-
tional Assessment of Cancer Therapy-Bone Pain (FACT-
BP), which was recently developed to assess bone pain
and its effects on quality of life. In an initial validation
study, this 16-item questionnaire demonstrated good internal
consistency reliability, construct validity, and sensitivity to
change [74]. A related questionnaire designed to assess
treatment satisfaction and convenience in this population
was also examined in this validation study. None of these
new condition-specific measures were used in clinical trials
of bisphosphonates meeting criteria for inclusion in the
current review. However, the FACT-BP is being used in
clinical trials, and results will likely be published in the
future. If these condition-specific measures are widely adop-
ted, they may substantially improve outcomes assessment in
future trials of treatments for bone metastases.
Even as new condition-specific measures are developed
and implemented, it is likely that previously existing PRO
measures of pain will continue to be used in many trials of
treatments for bone metastases. There are four steps authors
can take when drafting manuscripts to enhance clarity. First,
we recommend explicitly stating when a measure is patient-
reported rather than clinician-reported. Second, clear and
accurate terminology should be used to identify and de-
scribe concepts. For example, there is a difference between
the terms “PRO measure” and “quality of life (QOL) mea-
sure.” PRO implies that the measure is completed directly
by patients, whereas QOL refers to the content of a measure,
indicating that it was designed to capture quality of life.
Despite this distinction, the literature in this field includes
examples of researchers erroneously referring to any PRO
measure as a QOL measure, even if the measure does not
assess QOL [75]. Third, all PRO measures should be clearly
named and/or described so that readers can understand
672 Support Care Cancer (2012) 20:657–677exactly how pain was assessed in each study. For example,
VAS and NRS measures should be clearly described, and
when measures have multiple versions, the version number
should be specified. Fourth, validated PRO measures should
be implemented according to instructions from instrument
developers, and any deviations from the instrument's
intended use and scoring approach should be specified. We
also recommend avoiding the use of unusual item subsets or
the creation of new composite scores derived from multiple
measures. These idiosyncratic approaches are not validated,
and they are difficult to interpret. Together, these four steps
will enhance clarity and consistency of results, while facil-
itating interpretation of findings and comparisons across
studies.
Several limitations of the current review should be ac-
knowledged. First, this review focused only on studies of
bisphosphonate treatment because this is the most common-
ly administered pharmaceutical treatment for patients with
bone metastases. Therefore, we cannot comment on PRO
measures used to assess pain related to other treatments such
as radiotherapy. Second, the literature search conducted for
this review only located articles that mentioned “pain” in the
abstract or title. There may be published trials of bisphosph-
onates that included measures of pain, but did not explicitly
mention pain in the title or abstract. Such articles are not
included in the current review. Third, this review did not
include a thorough search for the complete psychometric
validation history of each instrument. It is possible that
some of these measures could have been validated in the
target population, although this was never mentioned in any
of the articles included in this review. Fourth, this review
focused on identifying and describing measures, rather than
reporting the results of each study. Therefore, we cannot
comment on which measures were most likely to reflect
change in patients' conditions.
Findings of the current review suggest that pain is often a
key outcome of trials examining treatment for bone metas-
tases. However, results also highlight the measurement chal-
lenges for the field as new treatments are introduced and
evaluated. Future research is needed to develop instruments
specifically for assessing pain in patients with bone metas-
tases, while validating previously existing measures for use
in this population. In recent years, the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) has led to some consensus among leading
researchers on the optimal measurement strategies for
assessing chronic pain in clinical trials [29, 30]. These
efforts have provided a multidisciplinary expert consensus
on recommended measures and interpretation of PRO
results. The inconsistencies revealed by the current review
suggest that a similar effort focusing on assessment of pain
associated with bone metastases would be a helpful first step
toward improving the evaluation of treatments for these
patients. With improved assessment tools, it may be possible
to identify treatments targeting specific types of pain expe-
rienced by patients with bone metastases.
Acknowledgements The authors thank Julie Meilak, Aria Gray,
Emily Sargent, and Nancy Brady for production assistance. This study
was funded by Amgen, Inc.
Conflicts of interest Karen Chung is an employee of Amgen. Louis
Matza, Brooke Currie, and Kate Van Brunt are employees of United
BioSource Corporation, a company that received funding from Amgen
for time spent completing this research. Lesley Fallowfield and Donald
Patrick were consultants who received funding from Amgen for time
spent on this research.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any non-
commercial use, distribution, and reproduction in any medium, provided
the original author(s) and source are credited.
References
1. Coleman RE (2001) Metastatic bone disease: clinical features,
pathophysiology and treatment strategies. Cancer Treat Rev
27:165–176
2. Coleman RE (2006) The role of bone markers in metastatic bone
disease. Cancer Treat Rev 32:1–2
3. Costa L, Lipton A, Coleman RE (2006) Role of bisphosphonates
for the management of skeletal complications and bone pain from
skeletal metastases. Support Cancer Ther 3:143–153
4. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P,
Body JJ, De Boer R, Berardi R, Gascon P, Tonkin KS, Coleman
R, Paterson AHG, Peterson MC, Fan M, Kinsey A, Jun S (2007)
Randomized active-controlled phase II study of denosumab effi-
cacy and safety in patients with breast cancer-related bone me-
tastases. J Clin Oncol 25:4431–4437
5. Hitron A, Adams V (2009) The pharmacological management of
skeletal-related events from metastatic tumors. Orthopedics
32:188
6. Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A,
Wu J, Shafiq J, Sezer O, Kardamakis D, Linden Y, Ma B, Castro
M, Arnalot PF, Ahmedzai S, Clemons M, Hoskin P, Yee A,
Brundage M, Bottomley A (2009) The European Organisation
forResearchandTreatmentofCancerQualityofLifeQuestionnaire
for patients with bone metastases: the EORTC QLQ-BM22. Eur J
Cancer 45:1146–1152
7. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning
GA, Schulman KA (2005) The significance of skeletal-related
events for the health-related quality of life of patients with meta-
static prostate cancer. Ann Oncol 16:579–584
8. Coleman RE (2004) Bisphosphonates: clinical experience. On-
cologist 9(Suppl 4):14–27
9. Coleman RE (2008) Risks and benefits of bisphosphonates. Br J
Cancer 98:1736–1740
10. Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W,
GorbunovaVA,BuddeM,BergstromB(2004)Improvedqualityof
life after long-term treatment with the bisphosphonate ibandronate
in patients with metastatic bone disease due to breast cancer. Eur J
Cancer 40:1704–1712
Support Care Cancer (2012) 20:657–677 67311. Smith MR (2003) Bisphosphonates to prevent skeletal complica-
tions in men with metastatic prostate cancer. J Urol 170:S55–S57,
discussion S57–S58
12. Wong R, Wiffen PJ (2002) Bisphosphonates for the relief of pain
secondary to bone metastases. Cochrane Database Syst Rev:
CD002068
13. Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T,
Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE (2006)
Phase II trial evaluating the palliative benefit of second-line
zoledronic acid in breast cancer patients with either a skeletal-
related event or progressive bone metastases despite first-line
bisphosphonate therapy. J Clin Oncol 24:4895–4900
14. WeinfurtKP,AnstromKJ,CastelLD,SchulmanKA,SaadF(2006)
Effect of zoledronic acid on pain associated with bone metastasis in
patients with prostate cancer. Ann Oncol 17:986–989
15. FoodandDrugAdministration(FDA)(2009)Guidanceforindustry
on patient-reported outcome measures: use in medical product
development to support labeling claims. Fed Regist 74:65132–
65133
16. Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha
S, O'Neill R, Kennedy DL (2007) Patient-reported outcomes to
support medical product labeling claims: FDA perspective value.
Health 10(Suppl 2):S125–S137
17. European Medicines Agency (2005) Reflection paper on the
regulatory guidance for the use of health related quality of life
(HRQL) measures in the evaluation of medicinal products.
European Medicines Agency, London
18. OkenMM,CreechRH,TormeyDC,HortonJ,DavisTE,McFadden
ET, Carbone PP (1982) Toxicity and response criteria of the
Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–
655
19. Karnofsky DA, Burchenal JH (1949) The clinical evaluation of
chemotherapeutic agents in cancer. In: Macleod CM (ed) Evalu-
ation of chemotherapeutic agents. Columbia University Press,
New York, pp 191–205
20. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD,
Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidr-
onate prevents skeletal complications and is effective palliative
treatment in women with breast carcinoma and osteolytic bone
metastases: long term follow-up of two randomized, placebo-
controlled trials. Cancer 88:1082–1090
21. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO (2003)
Combined analysis of two multicenter, randomized, placebo-
controlled studies of pamidronate disodium for the palliation of
bone pain in men with metastatic prostate cancer. J Clin Oncol
21:4277–4284
22. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev
AF, Tripathy D, Bergstrom B (2004) Oral ibandronate improves
bone pain and preserves quality of life in patients with skeletal
metastases due to breast cancer. Pain 111:306–312
23. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W,
Gorbunova VA, Budde M, Bergstrom B (2003) Intravenous ibandr-
onate reduces the incidence of skeletal complications in patients
with breast cancer and bone metastases. Ann Oncol 14:1399–1405
24. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt
J, Budde M, Bergstrom B (2004) Oral ibandronate for the treatment
ofmetastaticbonediseaseinbreastcancer:efficacy and safetyresults
from a randomized, double-blind, placebo-controlled trial. Ann
Oncol 15:743–750
25. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Guercio S, Torta M,
Tampellini M, Dovio A, Poggio M, Scarpa RM, Angeli A (2002)
Metabolic effects of single-dose pamidronate administration in
prostate cancer patients with bone metastases. Int J Biol Markers
17:244–252
26. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE (2001)
Comparison of the effects of intravenous pamidronate and oral
clodronate on symptoms and bone resorption in patients with
metastatic bone disease. Ann Oncol 12:1433–1438
27. Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C,
Dimopoulos T, Koutsilieris M (2006) Randomized controlled
clinicaltrialofacombinationofsomatostatin analoganddexameth-
asone plus zoledronate vs. zoledronate in patients with androgen
ablation-refractory prostate cancer. Anticancer Res 26:3693–3700
28. Wang RF, Zhang CL, Zhu SL, Zhu M (2003) A comparative study
of samarium-153-ethylenediaminetetramethylene phosphonic acid
with pamidronate disodium in the treatment of patients with painful
metastatic bone cancer. Med Princ Pract 12:97–101
29. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen
MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr
DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad
AR, Kramer LD, Manning DC, Martin S, McCormick CG,
McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins
W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW,
Stein W, Tollett J, Wernicke J, Witter J (2005) Core outcome
measures for chronic pain clinical trials: IMMPACT recommen-
dations. Pain 113:9–19
30. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS,
Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN,
Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P,
Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet
H, Kramer LD, Manning DC, McCormick C, McDermott
M P ,M c Q u a yH J ,P a t e lS ,P o r t e rL ,Q u e s s yS ,R a p p a p o r t
BA, Rauschkolb C, Revicki DA, Rothman M, Schmader
KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J,
Zavisic S (2008) Interpreting the clinical importance of treatment
outcomes in chronic pain clinical trials: IMMPACT recommenda-
tions. J Pain 9:105–121
31. Jensen MP (2003) The validity and reliability of pain measures in
adults with cancer. J Pain 4:2–21
32. Cleeland CS, Ryan KM (1994) Pain assessment: global use
of the Brief Pain Inventory. Ann Acad Med Singapore
23:129–138
3 3 .B e r e n s o nJ R ,R o s e nL S ,H o w e l lA ,P o r t e rL ,C o l e m a nR E ,
Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ (2001)
Zoledronic acid reduces skeletal-related events in patients with
osteolytic metastases. Cancer 91:1191–1200
34. Mystakidou K, Stathopoulou E, Parpa E, Kouloulias V, Kouskouni
E, Vlahos L (2008) Oral versus intravenous ibandronic acid: a
comparison of treatment options for metastatic bone disease. J
Cancer Res Clin Oncol 134:1303–1310
35. Cleeland C (2009) The Brief Pain Inventory user guide. The
University of Texas MD Anderson Cancer Center, Houston
36. Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift
RA, Conde F, Von Teichert JM (2001) A phase I, open label, dose
ranging trial of intravenous bolus zoledronic acid, a novel
bisphosphonate, in cancer patients with metastatic bone disease.
Cancer 91:144–154
37. Daut RL, Cleeland CS, Flanery RC (1983) Development of the
Wisconsin Brief Pain Questionnaire to assess pain in cancer and
other diseases. Pain 17:197–210
38. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore
MJ, Chi K, Ding K, Elliott C, Parulekar W (2003) Randomized,
double-blind, controlled trial of mitoxantrone/prednisone and
clodronate versus mitoxantrone/prednisone and placebo in patients
with hormone-refractory prostate cancer and pain. J Clin Oncol
21:3335–3342
39. MelzackR(1975)TheMcGillPainQuestionnaire:major properties
and scoring methods. Pain 1:277–299
40. Melzack R (1987) The short-form McGill Pain Questionnaire.
Pain 30:191–197
41. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart
JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD,
674 Support Care Cancer (2012) 20:657–677Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces
skeletal morbidity in women with advanced breast cancer and lytic
bone lesions: a randomized, placebo-controlled trial. Protocol 18
Aredia Breast Cancer Study Group. J Clin Oncol 17:846–854
42. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A,
Nuzzo V, Abbruzzese A, Lupoli G (2001) Pamidronate improves
the quality of life and induces clinical remission of bone
metastases in patients with thyroid cancer. Br J Cancer 84:1586–
1590
43. Huskisson EC (1974) Measurement of pain. Lancet 2:1127–1131
44. Huskisson EC (1982) Measurement of pain. J Rheumatol 9:768–
769
45. Scott J, Huskisson EC (1976) Graphic representation of pain.
Pain 2:175–184
46. Iwamoto J, Takeda T, Ichimura S (2002) Transient relief of
metastatic cancer bone pain by oral administration of etidronate.
J Bone Miner Metab 20:228–234
47. Nelson E, Wasson J, Kirk J, Keller A, Clark D, Dietrich A,
Stewart A, Zubkoff M (1987) Assessment of function in routine
clinical practice: description of the COOP Chart method and
preliminary findings. J Chronic Dis 40(Suppl 1):55S–69S
48. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A,
Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al
(1993) The European Organization for Research and Treatment of
Cancer QLQ-C30: a quality-of-life instrument for use in interna-
tional clinical trials in oncology. J Natl Cancer Inst 85:365–376
49. Fayers P, Bottomley A (2002) Quality of life research within the
EORTC-the EORTC QLQ-C30. Eur Org Res Treat Cancer Eur J
Cancer 38(Suppl 4):S125–S133
50. Manas A, Casas F, Ciria JP, Lopez C, Saez J, Palacios A, de las
Heras M, Porto C, Sanchez E, Martin C, Esco R, Veiras C,
Martinez JC, Marquez M, Ramos A, Calvo F, Fuertes J, Andreu
FJ, Contreras J, Perez L, Romero J, Vayreda J, Victoria C (2008)
Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic
radiotherapy plus zoledronic acid in patients with bone metasta-
ses. Clin Transl Oncol 10:281–287
51. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J,
Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic
acid significantly improves pain scores and quality of life in breast
cancerpatientswithbonemetastases:arandomised,crossoverstudy
of community vs hospital bisphosphonate administration. Br J
Cancer 92:1869–1876
52. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A,
Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull
A, Aaronson NK (1996) The European Organization for Research
and Treatment of Cancer breast cancer-specific quality-of-life
questionnaire module: first results from a three-country field
study. J Clin Oncol 14:2756–2768
53. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A,
Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The
functional assessment of cancer therapy scale: development and
validation of the general measure. J Clin Oncol 11:570–579
54. Webster K, Cella D, Yost K (2003) The Functional Assessment of
Chronic Illness Therapy (FACIT) measurement system: properties,
applications, and interpretation. Health Qual Life Outcomes 1:79
55. FACIT (2009) FACIT (Functional Assessment of Chronic Illness
Therapy). FACIT, Elmhurst
56. Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano
S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli
RV, Zeppetella GL (2007) The clinical response on bone metastasis
frombreastandlungcancerduringtreatmentwithzoledronicacidis
inversely correlated to skeletal related events (SRE). J Exp Clin
Cancer Res 26:307–312
57. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P,
Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A
randomized, placebo-controlled trial of zoledronic acid in patients
with hormone-refractory metastatic prostate carcinoma. J Natl
Cancer Inst 94:1458–1468
58. Brooks R, Rabin R, de Charro F (2003) The measurement and
valuation of health status using EQ-5D: a European perspective.
Kluwer Academic Publishers, Dordrecht
59. EuroQol Group (1990) EuroQol—a new facility for the measure-
ment of health-related quality of life. The EuroQol Group. Health
Policy 16:199–208
60. Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF (1998)
Responsiveness to change in health-related quality of life in a
randomized clinical trial: a comparison of the Prostate Cancer
Specific Quality of Life Instrument (PROSQOLI) with analogous
scales from the EORTC QLQ-C30 and a trial specific module.
Eur Org Res Treat Cancer J Clin Epidemiol 51:137–145
61. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart
L, Rider W (1989) Treatment of metastatic prostatic cancer with
low-dose prednisone: evaluation of pain and quality of life as
pragmatic indices of response. J Clin Oncol 7:590–597
62. Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of
ibandronateinthetreatmentofopioid-resistantbonepainassociated
with metastatic bone disease: a pilot study. J Clin Oncol 22:3587–
3592
63. BrueraE,KuehnN,Miller MJ, Selmser P,MacmillanK(1991)The
Edmonton Symptom Assessment System(ESAS): a simple method
for the assessment of palliative care patients. J Palliat Care 7:6–9
64. Chang VT, Hwang SS, Feuerman M (2000) Validation of the
edmonton symptom assessment scale. Cancer 88:2164–2171
65. Mystakidou K, Katsouda E, Parpa E, Kouskouni E, Chondros C,
TsiatasML,GalanosA,VlahosL(2006) Aprospectiverandomized
controlledclinicaltrialofzoledronicacidforbonemetastases.AmJ
Hosp Palliat Care 23:41–50
66. Cella DF (1995) Measuring quality of life in palliative care. Semin
Oncol 22:73–81
67. Higgins JPT, Green S (2008) Cochrane handbook for systematic
reviews of interventions. The Cochrane Collaboration. Wiley,
Chichester
68. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert
AJ, Cohen R, Dow L (2009) Cancer-related pain: a pan-European
survey of prevalence, treatment, and patient attitudes. Ann Oncol
20:1420–1433
69. Leidy NK, Revicki DA, Geneste B (1999) Recommendations for
evaluating the validity of quality of life claims for labeling and
promotion value. Health 2:113–127
70. Scientific Advisory Committee of the Medical Outcomes Trust
(2002) Assessing health status and quality-of-life instruments:
attributes and review criteria. Qual Life Res 11:193–205
71. Leidy NK, Vernon M (2008) Perspectives on patient-reported
outcomes: content validity and qualitative research in a changing
clinical trial environment. PharmacoEconomics 26:363–370
72. Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie
CD (2009) Use of existing patient-reported outcome (PRO)
instruments and their modification: the ISPOR good research
practices for evaluating and documenting content validity for
the use of existing instruments and their modification PRO task
force report. Value Health 12:1075–1083
73. Jensen MP, Mardekian J, Lakshminarayanan M, Boye ME (2008)
Validity of 24-h recall ratings of pain severity: biasing effects of
“Peak” and “End” pain. Pain 137:422–427
74. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons C,
Ooi W, Cella D (2009) Switching breast cancer patients with
progressive bone metastases to third-generation bisphosphonates:
measuring impact using the functional assessment of cancer
therapy-bone pain. J Pain Symptom Manage 38:244–257
75. Tharmalingam S, Chow E, Harris K, Hird A, Sinclair E (2008)
Quality of life measurement in bone metastases: a literature
review. J Pain Res 1:49–58
Support Care Cancer (2012) 20:657–677 67576. Carteni G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia
V, Rondena R, Amadori D (2006) Efficacy and safety of zole-
dronic acid in patients with breast cancer metastatic to bone: a
multicenter clinical trial. Oncologist 11:841–848
77. Clemons M, Dranitsaris G, Ooi W, Cole DE (2008) A phase II
trial evaluating the palliative benefit of second-line oral ibandro-
nate in breast cancer patients with either a skeletal related event
(SRE) or progressive bone metastases (BM) despite standard
bisphosphonate (BP) therapy. Breast Cancer Res Treat 108:79–
85
78. Di Lorenzo G, Autorino R, Perdona S, De Laurentiis M,
D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N,
Altieri V, Tortora G, Figg WD, De Placido S (2007) Docetaxel,
vinorelbine, and zoledronic acid as first-line treatment in patients
with hormone refractory prostate cancer: a phase II study. Eur
Urol 52:1020–1027
79. Hong SJ, Cho KS, Cho HY, Ahn H, Kim CS, Chung BH (2007)
A prospective, multicenter, open-label trial of zoledronic acid in
patients with hormone refractory prostate cancer. Yonsei Med J
48:1001–1008
80. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey
J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman
JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidro-
nate in the treatment of skeletal metastases in patients with breast
cancer or osteolytic lesions of multiple myeloma: a phase III,
double-blind, comparative trial. Cancer J 7:377–387
81. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V,
Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz
G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo
in the treatment of skeletal metastases in patients with lung cancer
and other solid tumors: a phase III, double-blind, randomized trial
—the Zoledronic Acid Lung Cancer and Other Solid Tumors
Study Group. J Clin Oncol 21:3150–3157
82. Foley KM (1997) Supportive care and quality of life. In: DeVita
VT, Hellman S, Rosenberg SA (eds) Cancer: principles and
practice of oncology. Lippincott-Raven Publishers, Philadelphia,
pp 2807–2812
83. Coleman RE (1994) Evaluation of bone disease in breast cancer.
Breast 3:73–78
84. Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L,
Guarrasi R, Rossi E, Cennamo G, Tonini G, Capasso E, Santini
D, Caraglia M, Del Prete S (2008) Management of pain in elderly
patients receiving infusion of zoledronic acid for bone metastasis:
a single-institution report. Support Care Cancer 16:209–214
85. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS
(1995) When is cancer pain mild, moderate or severe? Grading
pain severity by its interference with function. Pain 61:277–284
86. Arican A, Icli F, Akbulut H, Cakir M, Sencan O, Samur M,
Acikgoz N, Demirkazik A (1999) The effect of two different
doses of oral clodronate on pain in patients with bone metastases.
Med Oncol 16:204–210
87. Sriwantanakul K et al (1983) Studies with different types of
visual analog scales for measurement of pain. Clin Pharmacol
Ther 34:234–239
88. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J,
Wallgren UB, Killany S, Andreassen L, Carlsson G, Fahl N,
Hatschek T, Sommer HH, Hessman Y, Hornmark-Stenstam B,
Johnsborg S, Klepp R, Laino R, Niklasson LG, Rudenstam CM,
SundbeckA,SoderbergM,TejlerG(1999)Efficacyofpamidronate
in breast cancer with bone metastases: a randomized, double-blind
placebo-controlled multicenter study. Anticancer Res 19:3383–
3392
89. Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C,
Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L,
Hohneker JA (2004) Safety and pain palliation of zoledronic acid
in patients with breast cancer, prostate cancer, or multiple myeloma
who previously received bisphosphonate therapy. Oncologist
9:687–695
90. Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio
MR, Di Fede G, Russo A, Vitale A, Rini GB, Casuccio A,
Intrivici C, Gebbia N (2005) The use of zoledronic acid in
patients with bone metastases from prostate carcinoma: effect
on analgesic response and bone metabolism biomarkers. J Chemo-
ther 17:555–559
91. Santangelo A, Testai M, Barbagallo P, Manuele S, Di Stefano A,
Tomarchio M, Trizzino G, Musumeci G, Panebianco P, Maugeri
D (2006) The use of bisphosphonates in palliative treatment of
bone metastases in a terminally ill, oncological elderly popula-
tion. Arch Gerontol Geriatr 43:187–192
92. Kaplan RM, Bush JW, Berry CC (1979) Health status index:
category rating versus magnitude estimation for measuring levels
of well-being. Med Care 17:501–525
93. Heidenreich A, Hofmann R, Engelmann UH (2001) The use of
bisphosphonate for the palliative treatment of painful bone metas-
tasisdue to hormone refractory prostatecancer.J Urol165:136–140
94. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the
treatment of prostate cancer associated painful osseous metasta-
ses. Prostate Cancer Prostatic Dis 5:231–235
95. Leto G, Badalamenti G, Arcara C, Crescimanno M, Flandina C,
Tumminello FM, Incorvaia L, Gebbia N, Fulfaro F (2006) Effects
of zoledronic acid on proteinase plasma levels in patients with
bone metastases. Anticancer Res 26:23–26
96. Bruera E, Michaud M, Vigano A, Neumann CM, Watanabe S,
Hanson J (2001) Multidisciplinary symptom control clinic in a
cancer center: a retrospective study. Support Care Cancer 9:162–
168
97. Jacox A, Carr DB, Payne R et al (1994) Management of cancer
pain: quick reference guide for clinicians. Clinical Practice
Guideline No. 9, AHCPR Publication No. 94-0592. Agency for
Health Care Policy and Research, United States Department of
Health and Human Services, Public Health Service, Washington
98. Rodrigues P, Hering F, Campagnari JC (2004) Use of bisphosph-
onates can dramatically improve pain in advanced hormone-
refractory prostate cancer patients. Prostate Cancer Prostatic Dis
7:350–354
99. Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A,
Soricelli A, Pace L, Salvatore M (2006) Combined therapy of Sr-
89 and zoledronic acid in patients with painful bone metastases.
Bone 39:35–41
100. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ,
Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA,
Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas
FD, Harrison KA (1998) Palliation of pain associated with meta-
static bone cancer using samarium-153 lexidronam: a double-
blind placebo-controlled clinical trial. J Clin Oncol 16:1574–
1581
101. Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E,
Leotsinides M, Kardamakis D (2007) Combination ibandronate
and radiotherapy for the treatment of bone metastases: clinical
evaluation and radiologic assessment. Int J Radiat Oncol Biol
Phys 67:264–272
102. Vassiliou V, Kalogeropoulou C, Giannopoulou E, Leotsinidis M,
Tsota I, Kardamakis D (2007) A novel study investigating the
therapeutic outcome of patients with lytic, mixed and sclerotic
bone metastases treated with combined radiotherapy and ibandr-
onate. Clin Exp Metastasis 24:169–178
103. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis
C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA,
Bamias A (2005) Combination of docetaxel, estramustine phos-
phate, and zoledronic acid in androgen-independent metastatic
prostate cancer: efficacy, safety, and clinical benefit assessment.
Urology 65:126–130
676 Support Care Cancer (2012) 20:657–677104. Coleman RE (1991) Assessment of response to treatment. In:
Rubens RD, Forgelman I (eds) Bone metastases: diagnosis and
treatment. Springer, New York, pp 99–120
105. Groff L, Zecca E, De Conno F, Brunelli C, Boffi R, Panzeri C,
Cazzaniga M, Ripamonti C (2001) The role of disodium pamidr-
onate in the management of bone pain due to malignancy. Palliat
Med 15:297–307
106. Martinetti A, Seregni E, Ripamonti C, Ferrari L, De Conno F,
Miceli R, Pallotti F, Coliva A, Biancolini D, Bombardieri E
(2002) Serum levels of tartrate-resistant acid phosphatase-5b in
breast cancer patients treated with pamidronate Int. J Biol
Markers 17:253–258
107. Martinetti A, Ripamonti C, Miceli R, Seregni E, Mariani L, De
Conno F, Bajetta E, Bombardieri E (2007) Short-term effects of
pamidronate on bone turnover: can bone markers be considered
predictive of the analgesic response? Oncol Rep 17:1533–1540
108. Ripamonti C, Fagnoni E, Campa T, Giardina V, Brunelli C, Pigni
A, De Conno F (2007) Decreases in pain at rest and movement-
related pain during zoledronic acid treatment in patients with
bone metastases due to breast or prostate cancer: a pilot study.
Support Care Cancer 15:1177–1184
109. Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M,
Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A
(2001) A phase I dose-ranging trial of monthly infusions of
zoledronic acid for the treatment of osteolytic bone metastases.
Clin Cancer Res 7:478–485
110. Tong D, Gillick L, Hendrickson FR (1982) The palliation of
symptomatic osseous metastases: final results of the study by
the Radiation Therapy Oncology Group. Cancer 50:893–899
111. Kouloulias VE, Dardoufas CE, Kouvaris JR, Antypas CE, Sandilos
PH, Matsopoulos GK, Vlahos LJ (2002) Use of image processing
techniques to assess effect of disodium pamidronate in conjunction
with radiotherapy in patients with bone metastases. Acta Oncol
41:169–174
112. Kouloulias V, Matsopoulos G, Kouvaris J, Dardoufas C, Bottomley
A, Varela M, Uzunoglu N, Antypas C, Metafa A, Moulopoulos A,
Sandilos P, Vlahos L (2003) Radiotherapy in conjunction with
intravenous infusion of 180 mg of disodium pamidronate in
management of osteolytic metastases from breast cancer: clinical
evaluation, biochemical markers, quality of life, and monitoring of
recalcification using assessments of gray-level histogram in plain
radiographs. Int J Radiat Oncol Biol Phys 57:143–157
113. Hillner BE, Weeks JC, Desch CE, Smith TJ (2000) Pamidronate
in prevention of bone complications in metastatic breast cancer: a
cost-effectiveness analysis. J Clin Oncol 18:72–79
114. KoulouliasVE,KouvarisJR,MystakidouK,VarelaMN,KokakisJ,
Pistevou-Gombaki K, Balafouta M, Gennatas C, Vlahos LJ (2004)
Duration of bisphosphonate treatment: results of a non-randomised
study in patients previously treated with local irradiation for bone
metastases from breast cancer. Curr Med Res Opin 20:819–826
115. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE
(1994) High-dose intravenous pamidronate for metastatic bone
pain. Br J Cancer 70:554–558
116. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD (1988)
Treatment of bone metastases from breast cancer with (3-amino-
1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer
58:621–625
117. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A,
Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996)
Efficacy of pamidronate in reducing skeletal complications in
patients with breast cancer and lytic bone metastases. Protocol 19
Aredia Breast Cancer Study Group. N Engl J Med 335:1785–1791
118. Price DD, Bush FM, Long S, Harkins SW (1994) A comparison
of pain measurement characteristics of mechanical visual ana-
logue and simple numerical rating scales. Pain 56:217–226
119. Lorish CD, Maisiak R (1986) The face scale: a brief, nonverbal
method for assessing patient mood. Arthritis Rheum 29:906–909
120. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D,
Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD,
Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention
of skeletal complications of metastatic breast cancer with pamidro-
nate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol
16:2038–2044
121. Fayers PM, Aaronson NK, Bjordal K et al (2001) European
Organization for Research and Treatment of Cancer QLQ-C30
scoring manual. EORTC Quality of Life Group, Brussels
Support Care Cancer (2012) 20:657–677 677